Glucotrack Settles $10.9M Debt Claim for $2M Cash Plus $2M Note
GCTK is trading near its 52-week low of $2.9 (10% above the low) on light trading volume (0.1× avg).
Summary
Glucotrack settled a $10.9 million disputed debt claim with Alto Opportunity Master Fund for $2 million cash, a $2 million convertible promissory note, and up to $125,000 in legal fees. The debt was owed by Apimeds Pharmaceuticals US, not Glucotrack directly, but Glucotrack is a settling party. This follows the 8-K filed today and the July reverse merger with Lokahi Therapeutics, which became the operating business. The settlement removes a significant legal overhang and reduces the cash outlay versus the claimed amount, though the convertible note adds potential dilution. Watch for details on conversion terms and impact on the September 11 special meeting.
At the time of this announcement, GCTK was trading at $3.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $2.90 to $212.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.